医学
安慰剂
血管性水肿
不利影响
内科学
临床终点
随机对照试验
临床试验
胃肠病学
病理
替代医学
作者
Martin Metz,A.M. Giménez-Arnau,Michihiro Hide,Mark Lebwohl,Giselle Mosnaim,Sarbjit Saini,Gordon Sussman,R. Szalewski,Sibylle Haemmerle,K. Lheritier,E.D. Martzloff,Noriko Seko,Pengpeng Wang,Artem Zharkov,Marcus Maurer
标识
DOI：10.1056/nejmoa2408792
摘要
Treatment with oral remibrutinib resulted in a significant improvement in a composite measure of itching and hives at week 12. (Funded by Novartis Pharmaceuticals; REMIX-1 and REMIX-2 ClinicalTrials.gov numbers, NCT05030311 and NCT05032157, respectively.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
你嵙这个期刊没买
Criminology34
热情依白
寻道图强
GingerF
zsyhcl
熬夜波比
Verity
Wind
tuanheqi
加菲丰丰
sswbzh
YifanWang
吼吼
morena
VDC
dxy
乌迪尔
andrele
啊z
MchemG
hey
冷静战斗机
tiptip
皖公网安备34019202002308
